CAR-T from cord blood in a patient with Ph+ acute lymphoblastic leukemia relapsing after hematopoietic stem cell transplantation.
Eur J Haematol
; 113(1): 127-129, 2024 Jul.
Article
in En
| MEDLINE
| ID: mdl-38644613
ABSTRACT
While there is intense interest in the production of allogeneic CAR-T cells from umbilical cord units, little is known about the reactivity and persistence of CAR-T cells of umbilical origin. We report the case of a patient at our hematological center with multiple relapsing Ph+ B-ALL, notably a Blinatunomab non-responder, who underwent therapy with Brexucabtagene Autoleucel following relapse on Ponatinib post-allogeneic hematopoietic stem cell transplantation. The patient achieved a rapid CAR-T expansion and durable remission presenting in good clinical conditions 6 months post-CAR-T infusion, without manifestations of graft-versus-host disease. The case report provides insight into the reactivity and persistence of CAR-T cells of umbilical origin, confirming the potential promise of allogeneic umbilical cord-derived CAR-T cells.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunotherapy, Adoptive
/
Hematopoietic Stem Cell Transplantation
/
Fetal Blood
Limits:
Humans
/
Male
Language:
En
Journal:
Eur J Haematol
/
Eur. j. haematol
/
European journal of haematology
Journal subject:
HEMATOLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Italia
Country of publication:
Reino Unido